STOCK TITAN

Insider plans 16,823-share sale in ALLO (NASDAQ: ALLO)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A holder of common stock has filed a Form 144 notice to potentially sell 16,823 shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $29,051.64. The issuer reports 224,730,144 shares of common stock outstanding.

The shares to be sold were acquired as restricted stock vesting under a registered plan on January 31, 2026, treated as compensation from the issuer. The same individual previously sold 786 common shares on November 17, 2025, generating gross proceeds of $958.92.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ALLO Form 144 filing disclose about upcoming share sales?

The Form 144 filing discloses a planned sale of 16,823 common shares with an indicated market value of $29,051.64. These shares may be sold on the NASDAQ through Morgan Stanley Smith Barney LLC, subject to Rule 144 conditions.

How many ALLO shares is the insider planning to sell under this Form 144?

The filer indicates an intent to sell 16,823 common shares. The filing also notes that the issuer has 224,730,144 common shares outstanding, providing context for the size of the potential transaction relative to total equity.

How and when were the ALLO shares in this Form 144 acquired?

The 16,823 shares were acquired as restricted stock vesting under a registered plan on January 31, 2026. The filing describes the nature of payment as compensation from the issuer rather than a cash purchase.

Has the ALLO insider sold any shares in the past three months?

Yes. The filing reports a prior sale of 786 common shares on November 17, 2025, generating $958.92 in gross proceeds. This historical activity is disclosed as required for sales during the preceding three months.

Which broker is handling the potential ALLO share sale in this Form 144?

The potential sale is designated to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The shares are expected to be sold on the NASDAQ market.

What is the approximate timing for the proposed ALLO share sale?

The filing lists an approximate date of sale of February 2, 2026 for the 16,823 common shares. This date reflects when the filer expects to begin selling the securities under Rule 144, subject to market conditions and applicable rules.
Allogene Therapeutics

NASDAQ:ALLO

ALLO Rankings

ALLO Latest News

ALLO Latest SEC Filings

ALLO Stock Data

391.03M
158.71M
17.45%
74.09%
8.99%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO